2014
DOI: 10.1016/j.msard.2014.09.188
|View full text |Cite
|
Sign up to set email alerts
|

Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

Abstract: Background: Natalizumab, a highly specific α4-integrin antagonist, , has recently been registered across the Middle East and North Africa region. It improves clinical and magnetic resonance imaging (MRI) outcomes and reduces the rate of relapse and disability progression in relapsing-remitting multiple sclerosis (MS). Natalizumab is recommended for patients who fail first-line disease-modifying therapy or who have very active disease. Progressive multifocal leukoencephalopathy is a rare, serious adverse event … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 41 publications
0
4
0
Order By: Relevance
“…Unlike other Middle Eastern countries, Kuwait, with its revised 2016 consensus guidelines, allows for all DMTs to be accessible, reimbursed and even escalated based on MRI activity alone (⩾3 new T2 or T1 Gd+ lesions). 1921 Australia does not have restrictive guidelines dictating treatment change, leaving autonomy in the hands of the clinician, but ranking only fourth in OR. One has to take into consideration that the contributing centres to MSBase care are mostly MS specialists, not general neurologists and, therefore, likely to take a more aggressive approach on the basis of evidence rather than national guidelines.…”
Section: Discussionmentioning
confidence: 99%
“…Unlike other Middle Eastern countries, Kuwait, with its revised 2016 consensus guidelines, allows for all DMTs to be accessible, reimbursed and even escalated based on MRI activity alone (⩾3 new T2 or T1 Gd+ lesions). 1921 Australia does not have restrictive guidelines dictating treatment change, leaving autonomy in the hands of the clinician, but ranking only fourth in OR. One has to take into consideration that the contributing centres to MSBase care are mostly MS specialists, not general neurologists and, therefore, likely to take a more aggressive approach on the basis of evidence rather than national guidelines.…”
Section: Discussionmentioning
confidence: 99%
“…Multiple sclerosis (MS) is the most common demyelinating disease that affects a sizable fraction of the young population at the age of their peak of productivity [3,4]. The incidence of MS has seen a progressive increase in the Middle East countries during the last two decades, with a 2:1 female‐to‐male ratio, similar to the ratio of MS worldwide [5,6]. The mechanisms underlying this gender bias are not fully understood [6–8].…”
Section: Introductionmentioning
confidence: 99%
“…Registries could help better locate individual patients and address their social and healthcare needs with trained professionals accordingly. Training Neurologists in this region will eventually result in earlier detection of disease so preventive measures could be taken to reduce comorbidities and decrease the long-term disability of patients(Al Tahan et al, 2014; Alroughani et al, 2014; Yamout et al, 2015).…”
Section: Discussionmentioning
confidence: 99%